Skip to content

Exploring the preventive effect of Sanwan acupoint filament implantation before chemotherapy on CINV: An open-label, three-arm randomized controlled trial

Exploring the preventive effect of Sanwan acupoint filament implantation before chemotherapy on CINV: An open-label, three-arm randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001178
Enrollment
Unknown
Registered
2026-05-07
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced nausea and vomiting (CINV)

Interventions

Standard treatment group:Ondansetron Injection 8mg + 0.9% Sodium Chloride Injection 20ml, intravenous injection
Burying thread + Standard treatment group:Add "Sanwan point" implantation therapy on the basis of standard treatment. The standard treatment protocol remains the same as before.
Sham implantation + Standard treatment group:In addition to the standard treatment, a sham acupuncture procedure was added at the Sanwan acupoint. The standard treatment protocol remains the same as b

Sponsors

Shaanxi Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet diagnostic criteria, have indications for chemotherapy without contraindications, require chemotherapy, or require adjuvant chemotherapy after surgery; 2. Age between 18 and 76 years; 3. Functional status score (Karnofsky Performance Status, KPS) >70 points; 4. Expected survival >3 months; 5. No nausea or vomiting symptoms and no use of antiemetic drugs within 24 hours prior to chemotherapy; 6. No symptoms of gastrointestinal obstruction; 7. Voluntary participation in this treatment plan and signed informed consent.

Exclusion criteria

Exclusion criteria: 1)Patients with brain metastasis from malignant tumors, increased intracranial pressure, gastrointestinal obstruction, brain tumors, cerebrovascular diseases, or other causes of refractory vomiting; 2) Patients with coagulation dysfunction, thrombocytopenia, or bleeding disorders; 3) Patients who have interrupted chemotherapy for other reasons; 4) Patients with severe skin damage or a history of protein allergy; 5) Patients with a history of needle syncope; 6) Late-stage critically ill patients; 7) Pregnant women, breastfeeding women, individuals with mental illness, or severe heart disease patients.

Design outcomes

Primary

MeasureTime frame
National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0;

Secondary

MeasureTime frame
Karnofsky Performance Status (KPS);Brief Fatigue Scale;Adverse Reaction Record;

Countries

China

Contacts

Public ContactHou Jun

Shaanxi Provincial Hospital of Traditional Chinese Medicine

274341300@qq.com18591994910

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026